Suchergebnisse - "Delaney, Rosemary"

PubPharm (7)

1

Subgroup analyses from the phase 3 ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer

enthalten in: NPJ breast cancer | 2024

von Hurvitz, S. | Bardia, A. | Punie, K. | +8

2

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02) : a randomised, open-label, multicentre, phase 3 trial

enthalten in: Lancet (London, England) | 2023

von Rugo, H. | Bardia, A. | Marmé, F. | +15

CommentIn: Nat Rev Clin Oncol. 2023 Nov;20(11):734. - PMID 37684406

3

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Rugo, H. | Bardia, A. | Marmé, F. | +13

CommentIn: J Clin Oncol. 2023 Feb 1;41(4):732-735. - PMID 36446052

4

Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancer-phase 3 ASCENT study subanalysis

enthalten in: NPJ breast cancer | 2022

von Carey, L. | Loirat, D. | Punie, K. | +17

5

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

enthalten in: Journal of clinical oncology | [2022]

von Rugo, H. | Bardia, A. | Marmé, F. | +13

6

TROPiCS-02 : A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer

enthalten in: Future oncology (London, England) | 2020

von Rugo, H. | Bardia, A. | Tolaney, S. | +9

7

A phase I study evaluating the effect of everolimus on the pharmacokinetics of midazolam in healthy subjects

enthalten in: Journal of clinical pharmacology | 2013

von Urva, S. | Bouillaud, E. | Delaney, R. | +2

1
[1]